Dr Reddy's Laboratories Receivables 2010-2025 | RDY
Dr Reddy's Laboratories receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
- Dr Reddy's Laboratories receivables for the quarter ending March 31, 2025 were $1.058B, a 9.87% increase year-over-year.
- Dr Reddy's Laboratories receivables for 2025 were $1.058B, a 9.87% increase from 2024.
- Dr Reddy's Laboratories receivables for 2024 were $0.963B, a 9.18% increase from 2023.
- Dr Reddy's Laboratories receivables for 2023 were $0.882B, a 0.23% increase from 2022.
Dr Reddy's Laboratories Annual Receivables
(Millions of US $) |
| 2025 |
$1,058 |
| 2024 |
$963 |
| 2023 |
$882 |
| 2022 |
$880 |
| 2021 |
$679 |
| 2020 |
$667 |
| 2019 |
$576 |
| 2018 |
$624 |
| 2017 |
$587 |
| 2016 |
$623 |
| 2015 |
$654 |
| 2014 |
$551 |
| 2013 |
$586 |
| 2012 |
$498 |
| 2011 |
$395 |
| 2010 |
$266 |
| 2009 |
$0 |
Dr Reddy's Laboratories Quarterly Receivables
(Millions of US $) |
| 2025-03-31 |
$1,058 |
| 2024-12-31 |
$1,078 |
| 2024-09-30 |
$1,008 |
| 2024-06-30 |
$973 |
| 2024-03-31 |
$963 |
| 2023-12-31 |
$943 |
| 2023-09-30 |
$839 |
| 2023-06-30 |
$939 |
| 2023-03-31 |
$882 |
| 2022-12-31 |
$907 |
| 2022-09-30 |
$946 |
| 2022-06-30 |
$927 |
| 2022-03-31 |
$880 |
| 2021-12-31 |
$839 |
| 2021-09-30 |
$926 |
| 2021-06-30 |
$821 |
| 2021-03-31 |
$679 |
| 2020-12-31 |
$728 |
| 2020-09-30 |
$681 |
| 2020-06-30 |
$617 |
| 2020-03-31 |
$667 |
| 2019-12-31 |
$622 |
| 2019-09-30 |
$576 |
| 2019-06-30 |
$549 |
| 2019-03-31 |
$576 |
| 2018-12-31 |
$535 |
| 2018-09-30 |
$636 |
| 2018-06-30 |
$700 |
| 2018-03-31 |
$624 |
| 2017-12-31 |
$665 |
| 2017-09-30 |
$646 |
| 2017-06-30 |
$637 |
| 2017-03-31 |
$587 |
| 2016-12-31 |
$605 |
| 2016-09-30 |
$555 |
| 2016-06-30 |
$526 |
| 2016-03-31 |
$623 |
| 2015-12-31 |
$633 |
| 2015-09-30 |
$654 |
| 2015-06-30 |
$661 |
| 2015-03-31 |
$654 |
| 2014-12-31 |
$638 |
| 2014-09-30 |
$609 |
| 2014-06-30 |
$601 |
| 2014-03-31 |
$551 |
| 2013-12-31 |
$562 |
| 2013-09-30 |
$532 |
| 2013-06-30 |
$490 |
| 2013-03-31 |
$586 |
| 2012-12-31 |
$497 |
| 2012-09-30 |
$496 |
| 2012-06-30 |
$449 |
| 2012-03-31 |
$498 |
| 2011-12-31 |
$498 |
| 2011-09-30 |
$419 |
| 2011-06-30 |
$384 |
| 2011-03-31 |
$395 |
| 2010-12-31 |
$314 |
| 2010-09-30 |
$288 |
| 2010-06-30 |
$275 |
| 2010-03-31 |
$266 |
| 2009-12-31 |
$250 |
| 2009-09-30 |
$272 |
| 2009-06-30 |
$280 |
| 2009-03-31 |
$287 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$12.582B |
$3.811B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
